Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FBXO25 CRISPR Activation Plasmid (h): sc-405092-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FBXO25 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- FBXO25 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by FBXO25 CRISPR Activation Plasmid (h) and FBXO25 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the FBXO25 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FBXO25 Antibody (G-5): sc-390219
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FBXO25 CRISPR Activation Plasmid (h) | sc-405092-ACT | 20 µg | $397.00 |
Human FBXO25 encodes an F-box protein that functions as a substrate-recognition component of SCF (SKP1–CUL1–F-box) E3 ubiquitin ligase complexes, helping direct specific proteins for ubiquitination and proteasome-dependent turnover. Through regulated protein degradation, FBXO25 contributes to control of cell cycle progression, stress-responsive signaling, and maintenance of proteostasis. Perturbation of SCF-mediated ubiquitin signaling can reshape transcriptional programs and cellular homeostasis, linking altered F-box activity to disease-relevant phenotypes in cancer biology and neurobiology. FBXO25 is therefore of interest for dissecting ubiquitin–proteasome pathway wiring and downstream effects on signaling and gene expression.
FBXO25 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FBXO25 expression without altering the underlying DNA sequence.
FBXO25 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FBXO25 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FBXO25 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous FBXO25 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FBXO25 locus and enabling the study of FBXO25-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of FBXO25 pathway restoration in tumor cells with silenced or reduced FBXO25 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.